FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  JOHANNESSEN JAN							2. Issuer Name <b>and</b> Ticker or Trading Symbol  Twist Bioscience Corp [ TWST ]								ationship k all appli Directo	cable)	Reporting Person(s) to Issuer ole) 10% Owner		
(Last) (First) (Middle) C/O TWIST BIOSCIENCE CORPORATION 681 GATEWAY BLVD.						3. Date of Earliest Transaction (Month/Day/Year) 11/17/2021									Officer below)	(give title		Other (s	specify
(Street) SOUTH SAN FRANCISCO CA 94080 (City) (State) (Zip)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	′				
		Tab	le I - No	n-Deriv	ative	Sec	urit	ies Ac	quired	, Dis	posed o	of, or Be	nefic	ially	Owned	i			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day)						r) E	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			nd 5) Securiti Benefic		es ally Following	Form (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership
								Code	v	Amount	(A) or (D)		9	Transac	saction(s) r. 3 and 4)			(Instr. 4)	
Common Stock 11/17/2						:021			М		5,000	5,000 A S		14	6,	6,898		D	
Common Stock 11/17/2					/2021	2021					5,000 D \$		\$11	5.17	1,	1,898		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	n Date,		ransaction ode (Instr.		of E		6. Date Exercisal Expiration Date (Month/Day/Year		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		De Se (Ir	Price of erivative ecurity 1str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amou or Numb of Share	er					
Director Stock Option (right to buy)	\$14	11/17/2021			М			5,000	(2)	:	10/29/2028	Common Stock	5,00	0	\$0	27,304	4	D	

## **Explanation of Responses:**

- 1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on February 17, 2021.
- 2. 1/3rd of the shares subject to the option vested and became exercisable on October 30, 2019, and 1/3rd of the shares subject to the option vest and become exercisable on each annual anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

## Remarks:

/s/ William Solis, as Attorneyin-Fact for Jan Johannessen

11/19/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.